JP2015521157A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521157A5
JP2015521157A5 JP2015504599A JP2015504599A JP2015521157A5 JP 2015521157 A5 JP2015521157 A5 JP 2015521157A5 JP 2015504599 A JP2015504599 A JP 2015504599A JP 2015504599 A JP2015504599 A JP 2015504599A JP 2015521157 A5 JP2015521157 A5 JP 2015521157A5
Authority
JP
Japan
Prior art keywords
cftr
subject
mucociliary clearance
kit
activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015504599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521157A (ja
JP6525203B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/032268 external-priority patent/WO2013151758A2/en
Publication of JP2015521157A publication Critical patent/JP2015521157A/ja
Publication of JP2015521157A5 publication Critical patent/JP2015521157A5/ja
Application granted granted Critical
Publication of JP6525203B2 publication Critical patent/JP6525203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015504599A 2012-04-06 2013-03-15 Cftr活性を増大させるための方法 Expired - Fee Related JP6525203B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621043P 2012-04-06 2012-04-06
US61/621,043 2012-04-06
PCT/US2013/032268 WO2013151758A2 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Publications (3)

Publication Number Publication Date
JP2015521157A JP2015521157A (ja) 2015-07-27
JP2015521157A5 true JP2015521157A5 (https=) 2016-05-12
JP6525203B2 JP6525203B2 (ja) 2019-06-05

Family

ID=49301152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015504599A Expired - Fee Related JP6525203B2 (ja) 2012-04-06 2013-03-15 Cftr活性を増大させるための方法

Country Status (8)

Country Link
US (2) US20150065539A1 (https=)
EP (1) EP2833885A4 (https=)
JP (1) JP6525203B2 (https=)
CN (1) CN104619321A (https=)
AU (2) AU2013243857A1 (https=)
CA (1) CA2869257A1 (https=)
HK (1) HK1206995A1 (https=)
WO (1) WO2013151758A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
HRP20180328T1 (hr) 2008-08-13 2018-04-20 Vertex Pharmaceuticals Inc. FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
KR20120068889A (ko) * 2009-09-12 2012-06-27 레키드 벤카이저 엘엘씨 뮤신 분비를 억제하기 위한 구아이페네신의 용도
KR101924162B1 (ko) * 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
US8471029B2 (en) * 2010-03-19 2013-06-25 Vertex Pharmaceutical Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP6063455B2 (ja) * 2011-05-18 2017-01-18 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたイバカフトルの誘導体

Similar Documents

Publication Publication Date Title
Giger et al. Biomedical applications of bisphosphonates
Schanté et al. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications
SG10201803833WA (en) Heterocyclic compounds useful in the treatment of disease
JP2016528301A5 (https=)
JP2014517008A5 (https=)
JP2015508103A5 (https=)
JP2016517888A5 (https=)
JP2018519245A5 (https=)
JP2018516238A5 (https=)
JP2016501221A5 (https=)
JP2017518302A5 (https=)
MX372775B (es) Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.
JP2013508279A5 (https=)
JP2015518491A5 (https=)
JP2016540749A5 (https=)
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
EA201400521A1 (ru) Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
JP2018521121A5 (https=)
JP2017500289A5 (https=)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2014506582A5 (https=)
JP2017014206A5 (https=)
JP2016513124A5 (https=)